Famotidine
- Generic Name
- Famotidine
- Brand Names
- Duexis, Duo Fusion, Fluxid, Good Sense Acid Reducer, Pepcid, Pepcid Complete, Zantac Reformulated Aug 2022
- Drug Type
- Small Molecule
- Chemical Formula
- C8H15N7O2S3
- CAS Number
- 76824-35-6
- Unique Ingredient Identifier
- 5QZO15J2Z8
- Background
Famotidine is a competitive histamine-2 (H) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H receptor antagonists, famotidine displays high selectivity to...
- Indication
Famotidine is indicated in pediatric and adult patients (with the bodyweight of 40 kg and above) for the management of active duodenal ulcer (DU), active gastric ulcer, symptomatic non-erosive gastroesophageal reflux disease (GERD), and erosive esophagitis due to GERD, diagnosed by biopsy.
...
- Associated Conditions
- Chronic Back Pain, Duodenal Ulcer, Erosive Esophagitis, Extra-Articular Rheumatism, Gastritis, Heartburn, Helicobacter Pylori Infection, Multiple Endocrine Neoplasia, Muscle Spasms, Nonspecific Pain Post Traumatic Injury, Osteoarthritis (OA), Postoperative pain, Stress Ulcers, Symptomatic Non-erosive Gastroesophageal Reflux Disease, Zollinger-Ellison Syndrome, Active Gastric ulcer, Acute Duodenal Ulcers, Gastrointestinal ulceration, Pathological hypersecretory conditions
- Associated Therapies
- -
A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients
- Conditions
- Interventions
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 495
- Registration Number
- NCT01499368
ASP (PPI_H2RA) Study-H2RA Versus PPI for the Prevention of Recurrent UGIB in High-risk Users of Low-dose ASA
- Conditions
- Interventions
- First Posted Date
- 2011-08-03
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 264
- Registration Number
- NCT01408186
- Locations
- 🇯🇵
Department of Gastroenterology, Osaka City General Hospital, Osaka, Japan (Satellite hospital of Osaka City University), Osaka, Japan
🇯🇵Department of Internal Medicine and Gastroenterology, Saga Medical School, Saga, Japan, Saga, Japan
🇯🇵Second Department of Internal Medicine, Osaka Medical College, Takatsuki, Osaka, Japan, Osaka, Japan
PPI vs H2RA in Patients With Helicobacter Pylori-Negative Idiopathic Bleeding Ulcers
- First Posted Date
- 2010-08-12
- Last Posted Date
- 2019-08-01
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 228
- Registration Number
- NCT01180179
- Locations
- 🇨🇳
Endoscopy Center, Prince of Wales Hospital, Shatin, Hong Kong, China
A Relative Bioavailability Study of 20 mg Famotidine Tablets Under Fasting Condition
- First Posted Date
- 2010-03-02
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Ranbaxy Laboratories Limited
- Target Recruit Count
- 32
- Registration Number
- NCT01079065
- Locations
- 🇮🇳
Ranbaxy Clinical Pharmacology Unit, Ranbaxy Laboratories Limited, Noida, Uttar Pradesh, India
A Relative Bioavailability Study of 20 mg Famotidine Tablets Under Fed Condition
- First Posted Date
- 2010-03-02
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Ranbaxy Laboratories Limited
- Target Recruit Count
- 24
- Registration Number
- NCT01079052
- Locations
- 🇮🇳
Ranbaxy Clinical Pharmacology Unit, Ranbaxy Laboratories Limited, Noida, Uttar Pradesh, India
A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054)
- Conditions
- Interventions
- First Posted Date
- 2009-10-23
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 18
- Registration Number
- NCT01000818
Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia
- First Posted Date
- 2009-09-16
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- Ruttonjee Hospital
- Target Recruit Count
- 128
- Registration Number
- NCT00978159
- Locations
- 🇨🇳
Queen Mary Hospital, Pokfulam, Hong Kong, China
🇨🇳Ruttonjee Hospital, Hong Kong, China
Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2007-11-29
- Last Posted Date
- 2012-03-20
- Lead Sponsor
- Jesper Ekelund
- Target Recruit Count
- 30
- Registration Number
- NCT00565175
- Locations
- 🇫🇮
Kellokosken sairaala, Kellokoski, Finland
🇫🇮Vaasa Hospital District, Vaasa, Finland
🇫🇮Lohjan sairaanhoitoalue, Lohja, Finland
Ulcer Prevention Study in Post Gastric Bypass Patients
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- University of Missouri-Columbia
- Target Recruit Count
- 40
- Registration Number
- NCT00557349
- Locations
- 🇺🇸
University of Missouri Health Care, Columbia, Missouri, United States
Study of XL281 in Adults With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2007-03-26
- Last Posted Date
- 2011-10-13
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 180
- Registration Number
- NCT00451880
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇺🇸Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.